Visilizumab

Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3 antigen on T-cells while exhibiting low Fc receptor binding activity to minimize activation-induced cytotoxicity. this unique design potentially suppresses the body's immune response through the modulation of T-cell function, and Visilizumab can be used in studies about the treatment of ulcerative colitis and Crohn's disease.